Phase II study of Tarceva [erlotinib] plus Temodar [temozolomide] during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma

Trial Profile

Phase II study of Tarceva [erlotinib] plus Temodar [temozolomide] during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Erlotinib; Temozolomide
  • Indications Brain cancer; Glioblastoma; Sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top